Autres langues Regeneron Pharmaceuticals, Inc.

Actions

REGN

US75886F1075

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 13/06/2025			Varia. 5j.	Varia. 1 janv.
529,24 ^USD	+1,42%		+7,30%	-25,70%

13/06	La fondatrice de 23andMe, Anne Wojcicki, remporte l'appel d'offres pour le rachat de la société de tests ADN	RE
13/06	23Andme conclut un accord pour la vente de ses activités à TTAM Research Institute	RE

Autres langues

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial	17:21
23andMe's founder Anne Wojcicki wins bid for bankrupt DNA testing firm	13/06
23Andme Reaches Agreement For Sale Of Business To TTAM Research Institute	13/06
23andMe's founder Anne Wojcicki wins bid for DNA testing firm	13/06
US states sue 23andMe to protect customers' private data	10/06
Valores destacados al cierre del mercado norteamericano	10/06
Regeneron, Sanofi Say Atopic Dermatitis Trial Shows Improvement in Disease Severity	09/06
Dupixent® (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color	08/06
Dupixent® (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color	08/06
23andMe seeks new bids after $305 million offer from its co-founder	05/06
Sanofi: struikelt na gemengde resultaten van klinische studies	02/06
Regeneron's weight-loss drug helps patients on Wegovy preserve muscle	02/06
Regeneron Says Phase 2 Obesity Study Interim Results Show Semaglutide Combination Preserves Lean Mass	02/06
Hansoh Pharmaceutical Says Units Entered Into A License Agreement With Regeneron Pharmaceuticals	02/06
Global markets live: Tesla, Sanofi, Apple, JPMorgan, Microsoft…	02/06
A Springtime Riddle on Wall Street	02/06
Regeneron Pharmaceuticals - Interim Results From Ongoing Phase 2 Courage Trial	02/06
Regeneron Expands Clinical-Stage Obesity Portfolio	02/06
Regeneron Pharmaceuticals Partners With Hansoh Pharma to Develop GLP-1 Drug	02/06
Regeneron Signs Licensing Agreement for Chinese Weight Loss Drug	02/06
Regeneron Says Libtayo Shows Strong Results in Adjuvant Skin Cancer Trial	02/06
Regeneron's weight-loss drug helps preserve muscle mass in study	02/06
Regeneron Expands Clinical-Stage Obesity Portfolio with Strategic In-Licensing of Novel Dual GLP-1/GIP Receptor Agonist	02/06
Regeneron Pharmaceuticals, Inc. Expands Clinical-Stage Obesity Portfolio with Strategic In-Licensing of Novel Dual Glp-1/Gip Receptor Agonist	02/06
Interim Results from Ongoing Phase 2 COURAGE Trial Confirm Potential to Improve the Quality of Semaglutide (GLP-1 receptor agonist)-induced Weight Loss by Preserving Lean Mass	02/06

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

A la une

Le directeur scientifique de Regeneron, M. Yancopoulos, parle des médicaments pour la perte de poids et du pipeline

Le 14 janvier 2025 à 18:24